Selected article for: "causative agent and current study"
Author: Abosheasha, Mohammed A.; El-Gowily, Afnan H.; Elfiky, Abdo A.
Title: Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective
  • Cord-id: i7fbqke7
  • Document date: 2021_9_12
    • ID: i7fbqke7
    Snippet: SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor
    Document: SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor, cilostazol, cangrelor, and prasugrel in binding the main protease (M(pro)) of SARS-CoV-2. At the same time, vorapaxar, ticagrelor, and cilostazol are the best binders of the spike protein. Therefore, these compounds could be successful candidates against COVID-19 that need to be tested experimentally. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-021-02558-5.

    Search related documents:
    Co phrase search for related documents
    • active site and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and lung damage: 1
    • active site and lung injury: 1, 2
    • active site dyad and acute respiratory syndrome: 1, 2, 3, 4
    • active site dyad and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • active site pocket and acute respiratory syndrome: 1, 2, 3
    • active site pocket and acute sars cov respiratory syndrome coronavirus: 1
    • acute respiratory syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung damage lead: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung damage lead: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25